Related Experiment Video
Updated: Jan 27, 2026

Rapid Homogeneous Detection of Biological Assays Using Magnetic Modulation Biosensing System
Published on: June 13, 2010
Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M4 Positive
Jeffrey W Schubert1, Scott T Harrison1, James Mulhearn1
1Department of Medicinal Chemistry, Merck & Co., Inc., West Point, PA, USA.
Researchers discovered novel muscarinic acetylcholine receptor 4 (M4) positive allosteric modulators (PAMs). Compound 24 demonstrates antipsychotic efficacy and a potentially improved safety profile compared to nonselective M4 agonists.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Muscarinic acetylcholine receptor 4 (M4) is a G protein-coupled receptor implicated in various neurological disorders.
- Positive allosteric modulators (PAMs) offer a potential therapeutic strategy by enhancing receptor function in a subtype-selective manner.
- Developing selective M4 PAMs with favorable pharmacokinetic and safety profiles remains a significant challenge.
Purpose of the Study:
- To discover and optimize novel 2,3-disubstituted and 2,3,6-trisubstituted M4 PAMs.
- To identify a potent, selective, brain-penetrant M4 PAM tool compound for preclinical studies.
- To evaluate the efficacy and safety profile of the optimized M4 PAM in animal models.
Main Methods:
- Iterative library synthesis and structure-activity relationship (SAR) studies to identify key structural features for potency and selectivity.
- In vitro assays to characterize receptor binding and functional activity.
- In vivo preclinical models, including amphetamine-induced hyperlocomotion in rats and mice, to assess antipsychotic-like efficacy.
- Pharmacokinetic and safety assessments, including evaluation of cholinergic-related adverse effects.
Main Results:
- Discovery of a new series of M4 PAMs with potent activity.
- Identification of compound 24, a selective, brain-penetrant M4 PAM.
- Compound 24 demonstrated dose-dependent efficacy in reversing amphetamine-induced hyperlocomotion in M4-expressing rodents, an effect absent in M4 knockout mice.
- Compound 24 exhibited a potentially improved safety profile with fewer and less severe cholinergic adverse effects compared to the nonselective M4 agonist xanomeline.
Conclusions:
- The identified M4 PAMs, particularly compound 24, represent promising candidates for further development.
- Selective M4 PAMs hold potential for treating neuropsychiatric disorders with an improved safety margin.
- Compound 24 serves as a valuable tool compound for investigating M4 receptor function in vivo.
Related Concept Videos
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Allosteric Regulation
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Drug Discovery: Overview

